SCHEMBL3523447

SCHEMBL3523447

O=c1ncc2ccccc2n1-c1cnc2ccccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR3A P46098 1/20 0.49
CYP11B1 P15538 1/20 0.46
CYP11B2 P19099 1/20 0.46
CHRNB2 P17787 1/20 0.42
CHRNA4 P43681 1/20 0.42
CYP1A2 P05177 1/20 0.41
HDAC1 Q13547 1/20 0.41
MGAM O43451 1/20 0.41
AKR1C3 P42330 1/20 0.40
ALDH1A1 P00352 2/20 0.40
DHFR P00374 1/20 0.39
PIK3CA P42336 3/20 0.38
PDGFRB P09619 2/20 0.37
PDGFRA P16234 2/20 0.37
TOP2A P11388 1/20 0.37
TOP2B Q02880 1/20 0.37
USP2 O75604 1/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
TSHR P16473 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12628244 0.80 ALDH1A1 (0.46) CYP1A2ALDH1A1GAATSHRKDM4E
SCHEMBL30615630 0.75 AURKA (0.56) TOP2ATOP2BTSHR
SCHEMBL1104835 0.74 MAPK1 (0.63) HTR3ACYP11B1CYP11B2CHRNB2CHRNA4
SCHEMBL3293262 0.73 NPC1 (0.35) HTR3AMGAMALDH1A1PDGFRBPDGFRA
SCHEMBL12792169 0.73 CYP11B1 (0.46) HTR3ACYP11B1CYP11B2CHRNB2CHRNA4
SCHEMBL30615331 0.72 DAO (0.47) HTR3ACYP11B1CYP11B2CHRNB2CHRNA4
SCHEMBL21463917 0.72 DAO (0.47) HTR3ACYP11B1CYP11B2CHRNB2CHRNA4
SCHEMBL15073544 0.72 CYP11B1 (0.44) HTR3ACYP11B1CYP11B2CHRNB2CHRNA4
SCHEMBL28752516 0.71 HSP90AA1 (0.56) HTR3ACYP11B1CYP11B2CHRNB2CHRNA4
SCHEMBL14924605 0.71 CYP11B1 (0.43) HTR3ACYP11B1CYP11B2CHRNB2CHRNA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7652006-B2 For therapy and prophylaxis of neuronal loss associated with stroke, global and focal ischemia, CNS trauma, hypoglycemia and surgery, for ameliorating neurodegenerative diseases EURO-CELTIQUE S.A. (LU) 2010-01-26 US disclosed